Valuation: Sera Prognostics, Inc.

Market Cap 86.15M 75.3M 69.64M 63.9M 121M 8.3B 123M 831M 326M 4.05B 324M 316M 14B P/E 2026 *
-3.36x
P/E 2027 * -3.93x
Enterprise Value 86.15M 75.3M 69.64M 63.9M 121M 8.3B 123M 831M 326M 4.05B 324M 316M 14B EV / Sales 2026 *
238x
EV / Sales 2027 * 32.2x
Free-Float
86.06%
Yield 2026 *
-
Yield 2027 * -
1 day+1.85%
1 week+6.80%
Current month+20.88%
1 month+18.28%
3 months-6.38%
6 months-39.89%
Current year-25.42%
1 week 1.9
Extreme 1.902
2.3
1 month 1.72
Extreme 1.725
2.3
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
13.51
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 31/05/2023
Director of Finance/CFO 39 06/06/2023
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 74 19/04/2011
Chairman 58 07/06/2023
Director/Board Member 59 31/10/2011
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Director

61,416 0.1608%
10/07/26 Free

Director

61,867 0.1620%
10/07/26 Free

Director

62,657 0.1641%
Change 5-day change 1-year change 3-year change Capi.($)
+1.85%+6.80%-25.93%-32.31% 86.15M
+0.77%+0.82%+14.68%+16.61% 23.22B
+0.22%+1.43%+23.89% - 18.08B
+0.94%+3.41%+15.97%-29.13% 3.44B
-9.46%-31.59%+41.09%+13.73% 2.8B
-6.28%-6.78%+151.70%+183.39% 2.08B
+1.82%+7.79%-34.34%-42.47% 1.91B
-0.06%-4.42%-1.82%+4.85% 1.57B
-3.35%-7.86%-41.26% - 1.54B
-6.72%-24.56%+132.82%+186.63% 1.46B
Average -2.03%-6.20%+27.68%+37.66% 5.62B
Weighted average by Cap. -0.46%-1.60%+23.45%+24.63%

Financials

2026 *2027 *
Net sales 362K 317K 293K 269K 509K 34.93M 518K 3.49M 1.37M 17.06M 1.36M 1.33M 58.89M 2.68M 2.34M 2.16M 1.98M 3.76M 258M 3.82M 25.79M 10.13M 126M 10.05M 9.83M 435M
Net income -33.26M -29.07M -26.89M -24.67M -46.7M -3.21B -47.51M -321M -126M -1.57B -125M -122M -5.4B -29.98M -26.2M -24.23M -22.24M -42.09M -2.89B -42.82M -289M -114M -1.41B -113M -110M -4.87B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
16/07/26 US$2.200 +1.85% 16,215
15/07/26 US$2.160 +9.09% 77,638
14/07/26 US$1.980 +3.13% 52,237
13/07/26 US$1.920 -2.54% 31,149
10/07/26 US$1.970 -4.37% 15,857
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.200USD
Average target price
5.500USD
Spread / Average Target
+150.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock